• 1
    Carter C. Pathogenesis of thrombosis. In: GreerIA, TurpieAGG, ForbesCD, editors. Haemostasis and Thrombosis in Obstetrics and Gynaecology. London : Chapman & Hall, 1992: 229256.
  • 2
    Jick H, Derby LE, Myers, MW, Vasilakis, C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981983.
  • 3
    Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Case control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 1996; 348: 977980.
  • 4
    Grodstein F, Stampfer MJ, Goldhaber SZ et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983987.
  • 5
    Gutthann SP, Garcia Rodrigues LA, Castallsague J, Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: population based case control study. BMJ 1997; 314: 796800.
  • 6
    Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: sex differences and effects of the menopause. BrJ Haematol 1994; 74: 7781.
  • 7
    Lindoff C, Peterson F, Lecander I, Martinsson G, Asted TB. Transdermal oestrogen replacement therapy: beneficial effects on haemostatic risk factors for cardiovascular disease. Maturitas 1996; 24; 4350.
  • 8
    The Writing Group for the Oestradiol Clotting Study. Effects on haemostasis of hormone replacement therapy with transdermal oestradiol and oral sequential medroxyprogesterone acetate: a one year double blind placebo controlled study. Thromb Heamostas 1996; 75: 476480.
  • 9
    Koh KK, Mincemoyer R, Bui MN et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 10: 683690.
  • 10
    Walker ID. Management of thrombophilia in pregnancy. Blood Rev 1991; 5: 227233.
  • 11
    Dahlback B, Hillarp A, Rosen S, Zoller B. Resistance to activated protein C, the FV Q506 allele and venous thrombosis. Ann Haematol 1996; 72: 166176.
  • 12
    Zoller B, Holm J, Dahlback B. Resistance to activated protein C due to a factor V gene mutation: the most common inherited risk factor of thrombosis. Trends Cardiovasc Med 1996; 6: 4553.
  • 13
    Hellgren M, Svensson PJ. and Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraception. Am J Obstet Gynecol 1995; 173: 210213.
  • 14
    Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk and interaction. Sem Hematol 1997; 34: 171187.
  • 15
    Lowe GDO, Rumley A, Woodward M, Reid E. Oral contraceptives and venous thromboembolism. Lancet 1997; 349: 1623.
  • 16
    Meinardi JR, Henkens CMA, Heringa MP, van der Meer J. Acquired APC resistance related to oral contraceptives and pregnancy and its possible implications for clinical practice. Blood Coag Fibrinol 1997: 349: 171187.
  • 17
    Poort SR, Rosendall FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′- untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 36983703.
  • 18
    Van der Mooren MJ, Vouters GAJ, Blom JH, Schellekens LA, Eskes TKAB, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994; 24: 733736.
  • 19
    Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V association with resistance to activated protein C. Nature 1994; 369: 6467.
  • 20
    Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ; 315: 149153.
  • 21
    Lowe GDO, Greer IA, Cooke TG et al. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567574.